Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)

计划入组 204 人 · 首次发布于 2026 年 1 月 8 日

SAL0137 Phase I Study in in Healthy Participants With or Without Elevated Lp(a)

计划入组 144 人 · 首次发布于 2026 年 8 月 4 日

A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)

计划入组 42 人 · 首次发布于 2014 年 9 月 16 日

LP-342

LP-922056

LP-08

Janssen LP

United States

AstraZeneca LP

United States

Covidien LP

United States

IL-6 Modifies Coronary Artery Disease Risk Associated with Elevated Lipoprotein(a), UK Biobank Study Finds

National Lipid Association Advocates for Universal Lipoprotein(a) Testing to Enhance Cardiovascular Risk Assessment

Lilly's Oral Muvalaplin Significantly Reduces Lipoprotein(a) Levels in Phase II Trial